Insider Buying: Altimmune, Inc. (NASDAQ:ALT) CFO Acquires 10,000 Shares of Stock

Altimmune, Inc. (NASDAQ:ALT) CFO Gregory L. Weaver acquired 10,000 shares of Altimmune stock in a transaction dated Thursday, March 13th. The shares were purchased at an average price of $5.20 per share, for a total transaction of $52,000.00. Following the completion of the transaction, the chief financial officer now directly owns 10,000 shares in the company, valued at approximately $52,000. The trade was a ? increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Altimmune Stock Up 13.8 %

ALT opened at $5.92 on Friday. The stock has a market cap of $455.92 million, a PE ratio of -3.82 and a beta of 0.87. The business has a 50 day moving average of $6.48 and a 200-day moving average of $7.11. Altimmune, Inc. has a 52 week low of $5.14 and a 52 week high of $11.16.

Altimmune (NASDAQ:ALT) last released its earnings results on Thursday, February 27th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. Equities analysts anticipate that Altimmune, Inc. will post -1.35 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on ALT shares. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research report on Monday, March 3rd. Stifel Nicolaus started coverage on Altimmune in a research report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price target on the stock. Finally, William Blair restated a “market perform” rating on shares of Altimmune in a research report on Friday. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $20.83.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ALT. Larson Financial Group LLC purchased a new position in Altimmune during the third quarter valued at $31,000. SBI Securities Co. Ltd. purchased a new position in Altimmune during the fourth quarter valued at $45,000. Virtus ETF Advisers LLC purchased a new position in Altimmune during the fourth quarter valued at $60,000. Cullen Frost Bankers Inc. bought a new stake in shares of Altimmune in the 4th quarter worth $72,000. Finally, 180 Wealth Advisors LLC bought a new stake in shares of Altimmune in the 4th quarter worth $78,000. Hedge funds and other institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.